Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 17/20 | 0.48 |
| ▸ | BRAF | P15056 | 11/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612795 | 0.91 | RAF1 (0.56) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL30439987 | 0.90 | RAF1 (0.57) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL22612925 | 0.90 | RAF1 (0.57) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL22612741 | 0.89 | RAF1 (0.58) | RAF1BRAF | |
| SCHEMBL30440072 | 0.89 | RAF1 (0.58) | RAF1BRAF | |
| SCHEMBL22612759 | 0.89 | RAF1 (0.50) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL22625555 | 0.89 | LCK (0.52) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL22612830 | 0.88 | LCK (0.54) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL22612725 | 0.88 | RAF1 (0.55) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL30440409 | 0.88 | LCK (0.54) | LCKKDRJAK3MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | LCK 19/4885KDR 113/4885JAK3 349/4885 |
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | LCK 19/4885KDR 113/4885JAK3 349/4885 |
| US-10927111-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | LCK 19/4885KDR 113/4885JAK3 349/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | LCK 19/4885KDR 113/4885JAK3 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.